Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CAB-AXL-ADC, BA3011
Mecbotamab vedotin (BA3011) · 3 trials · 4 indications
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5
Assess dose limiting toxicity as defined in the protocol
Frequency and severity of AEs and/or SAEs, and changes from baseline in laboratory parameters and vital signs
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Durvalumab + BA3011 (Arm Closed) | EXPERIMENTAL | - |
| Durvalumab + BA3021 (Arm Closed) | EXPERIMENTAL | - |
| ENB-003 + Toripalimab | EXPERIMENTAL | - |
| CAB-AXL-ADC (BA3011) | EXPERIMENTAL | CAB-AXL-ADC (BA3011) alone |
| CAB-AXL-ADC (BA3011)+PD-1 inhibitor | EXPERIMENTAL | CAB-AXL-ADC (BA3011) with PD-1 inhibitor |
| BA3011 | EXPERIMENTAL | Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor. |
| Combination Therapy | EXPERIMENTAL | Phase 2: BA3011 in combination with PD-1 inhibitor. |
| Name | Type | Description |
|---|---|---|
| Durvalumab | DRUG | 1500mg IV, 60 min day 1 every 4 weeks |
| BA3011 | DRUG | IV |
| BA3021 | DRUG | IV |
| ENB003 | DRUG | IV |
| Toripalimab | DRUG | IV |
| CAB-AXL-ADC | BIOLOGICAL | Conditionally active biologic anti-AXL antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * This study will enroll women with platinum resistant high grade serous ovarian cancer. * This study is open to minorities as appropriate but is not designed to measure differences in intervention effects. * All patients must be registered for screening prior to study enrollmen...
Top 20 of 79 competitors
Mecbotamab vedotin is an investigational antibody-drug conjugate being studied in oncology for non-small-cell lung cancer, ovarian cancer, and undifferentiated pleomorphic sarcoma. It is not yet approved and remains in clinical development under BioAtla, Inc. across these tumor types.
Mecbotamab vedotin is an antibody-drug conjugate that targets AXL, a receptor tyrosine kinase. The antibody component is designed to bind AXL, delivering a cytotoxic payload to tumor cells. It is being developed by BioAtla, Inc. as a targeted therapy for solid tumors.
Mecbotamab vedotin is developed by BioAtla, Inc., which trades under the ticker BCAB. BioAtla is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics, including this AXL-targeting antibody-drug conjugate.
Mecbotamab vedotin is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 studies are evaluating the drug in non-small-cell lung cancer and ovarian cancer, while an earlier Phase 1 study was conducted in sarcoma.
Mecbotamab vedotin has been studied in three clinical trials. NCT04918186 is a recruiting Phase 2 trial in platinum-resistant high-grade serous ovarian cancer. NCT04681131 was a completed Phase 2 trial in non-small-cell lung cancer. NCT03425279 was a completed Phase 1 trial in sarcoma.
Yes, mecbotamab vedotin is also known as BA3011 and CAB-AXL-ADC. These names refer to the same antibody-drug conjugate developed by BioAtla, Inc. The CAB designation reflects the company's conditionally active biologic platform, and BA3011 is the internal code for the asset.